Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
Under what circumstances would it be appropriate to offer trimodality therapy (TMT) in muscle-invasive bladder cancer with localized variant histology?
Related Questions
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
Would you add pembrolizumab to enfortumab to further treat a patient with metastatic bladder cancer that progressed on avelumab maintenance after cis/gem?
Based on the results of the BladderPath trial, are you considering multiparametric bladder MRI for all patients with suspected bladder cancer diagnosis prior to TURBT, or for select patients only?
How do you manage dysgeusia from Enfortumab Vedotin?
Would you give any adjuvant therapy (chemo, immunotherapy and/or radiation) to a patient with pure small cell cancer of the urinary bladder who received neoadjuvant cisplatin and etoposide but had pN+ and residual invasive disease on cystectomy?
In patients with localized small cell bladder cancer, would you consider consolidation with durvalumab after neoadjuvant chemotherapy followed by definitive local therapy (cystectomy or RT)?
Would you recommend "adjuvant" immunotherapy in a older, frail patient who received radiation for upper tract urothelial carcinoma?
Are patients with MIBC and bladder neck involvement good candidates for bladder preservation with chemoradiation after maximal, but not complete, TURBT?
What is your approach to a patient with muscle invasive bladder cancer getting neoadjuvant gemcitabine/cisplatin who develops significant ototoxicity due to cisplatin after two cycles?
Would you consider neoadjuvant immunotherapy in a patient with Lynch syndrome and urothelial cancer?
